Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
ORLANDO, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Today’s featured company is a simple story. It’s a uranium...
Company Announcement IND for HuMax(R)-TF-ADC submitted to FDA Genmab's first IND submission for antibody-drug conjugate (ADC) product...
Company Announcement Genentech and Biogen Idec refused re-hearing in Arzerra patent infringement case COPENHAGEN, Denmark, July 15, 2013...
Company Announcement First Phase III study with subcutaneous formulation of ofatumumab Ofatumumab to be investigated in new autoimmune...
Media Release Antibody-drug conjugate (ADC) to be developed for cancer Combines strength of HuMax(R)-TAC with next generation...
Company Announcement Teprotumumab (RG1507) to be investigated for new indication River Vision Development Corporation to conduct...
Company Announcement Genmab establishes Sponsored Level 1 ADR program Genmab ADRs can be traded on US over-the-counter (OTC) market...
Company Announcement Median 22.4 month progression free survival in patients treated with ofatumumab plus chlorambucil, an improvement of...
Company Announcement Genentech and Biogen Idec have filed for re-hearing in the United States COPENHAGEN, Denmark, May 17, 2013 (GLOBE...
COPENHAGEN, Denmark, May 7, 2013 (GLOBE NEWSWIRE) -- Interim Report First Quarter 2013 Arzerra(r) received approval in Japan Arzerra net...
Company Announcement 95% overall response rate and 43% complete response rate in patients with previously untreated chronic lymphocytic...
Company Announcement Daratumumab receives Breakthrough Therapy Designation in double refractory multiple myeloma Potential for...
Company Announcement Arzerra worldwide net sales in Q1 2013 totaled GBP 20.5 million Genmab expects royalty payment of DKK 36 million...
Company Announcement At Genmab A/S' Annual General Meeting held today on April 17, 2013 the Annual Report for 2012 was...
Company Announcement Final ruling of U.S. Court of Appeals in favor of GSK in Arzerra patent infringement case COPENHAGEN, Denmark, April...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지